Johnson & Johnson (JNJ) Cash & Equivalents (2009 - 2026)

Johnson & Johnson (JNJ) has 18 years of Cash & Equivalents data on file, last reported at $21.7 billion in Q1 2026.

• Quarterly Cash & Equivalents fell 43.63% year-over-year to $21.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.7 billion (down 43.63% YoY) and the FY2025 annual result came in at $19.7 billion, down 18.24% from the prior year.
• Cash & Equivalents rose to $21.7 billion in Q1 2026 per JNJ's latest filing, from $19.7 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $38.5 billion in Q1 2025, with the low at $10.5 billion in Q2 2022.
• Average Cash & Equivalents over 5 years is $19.6 billion, with a median of $19.7 billion recorded in 2023.
• Year-over-year, Cash & Equivalents surged 92.87% in 2023 and plunged 43.63% in 2026.
• Johnson & Johnson's Cash & Equivalents stood at $11.4 billion in 2022, then soared by 92.51% to $21.9 billion in 2023, then advanced by 10.27% to $24.1 billion in 2024, then slipped by 18.24% to $19.7 billion in 2025, then advanced by 10.04% to $21.7 billion in 2026.
• Business Quant data shows JNJ's Cash & Equivalents at $21.7 billion in Q1 2026, $19.7 billion in Q4 2025, and $18.2 billion in Q3 2025.